Navigation Links
CISBIO Bioassays Launches Chromoa(TM) Chromogranin A ELISA Kit

Company's Expertise in Chromogranin A Tumor Detection Marker Technology Now

Applied to Universal Technique

BAGNOLS-SUR-CEZE, France, September 23 /PRNewswire/ -- CISBIO Bioassays, a member of IBA group and a developer and marketer of diagnostic assays for the quantification of tumor markers, announced today the launch of its chromogranin A ELISA diagnostic tool, Chromoa. This ELISA kit complements CISBIO's existing chromogranin A RIACT kit and can be used by all laboratories for the detection and monitoring of neuroendocrine tumors.

Chromoa is a highly-sensitive, monoclonal antibody-based assay used to identify increased protein levels in serum when a neuroendocrine tumor is present in the human body. The most common neuroendocrine tumors affect the adrenal gland, the pancreas and the digestive track. Chromogranin A (CgA) is an increasingly essential analyte for the detection and monitoring of these tumors as well as prostate cancer, which can evolve into an aggressive, neuroendocrine form.

CGA-RIACT has long been part of CISBIO'S tumor markers detection portfolio and its analytical and clinical performance has been documented in scientific publications for over a decade. Based on the same monoclonal antibody as CGA-RIACT, Chromoa offers the same reliable results but in an ELISA format. This new kit features a longer shelf life and offers easier stock management for technicians, making it a convenient, time and cost saving alternative. Particularly suitable for laboratories that do not use radioactive kits, enzyme-linked immunosorbent assays (ELISA) have been used for the quantitative analysis of protein blood samples for two decades and can be adopted by any laboratory.

Chromoa is marketed worldwide by CISBIO and its distribution network. In the U.S., the kit is available for research use only.

About CISBIO Bioassays

CISBIO Bioassays develops, manufactures and markets diagnostic assays for the quantification of tumor markers and other biomarkers in clinical biology. In addition, CISBIO is a global developer of products and technologies that are used in assay development for drug screening procedures and produces a selection of biological reagents and methods used by pharmaceutical and biotechnology companies and contract research organizations (CROs). Headquartered in Bagnols-sur-Ceze, France, CISBIO is a member of the IBA group. IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index. For more information about CISBIO and IBA:

Chromoa(TM) is a trademark of CISBIO Bioassays.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
2. Histogen Launches BioNuesis, the Only All-Human Stem Cell Culturing Kit
3. Sigma-Aldrich Launches Breakthrough Genome-Editing Tools
4. Lena Chow, Veteran Biotech Marketer, Launches New Website
5. BioSpace Launches Life Science Career Content and Resources from the Biotech Work Portal
6. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
7. Caliper Launches Small Animal Molecular Imaging System Enabling Real-Time Video Observation
8. SACHEM Launches 2-D HPLC e-Learning Program : New e-Learning Program Teaches Scientists How to Better Analyze and Prove Product Purity Through Greater Sensitivity and Precision in Identification of Trace Components
9. Familybuilder Launches the Familybuilder Global Network at DEMOfall 08
10. SearchMedica Launches Practice Management Search Engine for Medical Professionals
11. BIOLOCK(TM) USA Launches Affordable Fingerprint door Locks for Homes and Offices
Post Your Comments:
(Date:10/13/2015)... , Oct. 13, 2015  According to ... services will reach $102 billion by the end ... of the health industry, as it is estimated ... result of laboratory tests. In addition to diagnosing ... to evaluate disease progression, monitor drug treatment and ...
(Date:10/13/2015)... ... October 13, 2015 , ... Exotic Automation & Supply ... and components, is opening its latest Parker Store retail location in Ann, Arbor, ... second major expansion in Metropolitan Detroit in less than a year. The Ann ...
(Date:10/13/2015)... NC (PRWEB) , ... October 13, 2015 , ... ... intensity focused ultrasound (HIFU) technologies, announced today that it received de novo clearance ... in the U.S. for the ablation of prostate tissue. Sonablate® is the ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... educational opportunities for school age children in the areas of Science, Technology, Engineering ... sectors of the national economy, and the program aims to increase the number ...
Breaking Biology Technology:
(Date:10/13/2015)... 2015 Global Next Generation Biometric ... Market . --> Mordor Intelligence is pleased ... Next Generation Biometric Market . ) ... (Logo: ) --> ... expected to increase to $23.8 billion by 2020 at ...
(Date:10/12/2015)... 2015 Research and Markets ( ... "Iris Recognition Market by Component (Hardware & Software), ... Others), Industry (Travel & Immigration, Military & Defense, ... 2020" report to their offering. ... Recognition Market worth 3627.90 Million USD by 2020 ...
(Date:10/7/2015)... GOTHENBURG, Sweden , October 8, 2015 ... estimates the revenues for Fingerprint Cards (FPC) during third quarter ... communicated revenue guidance of around 860 MSEK that was communicated ... Considering a further strengthened delivery capacity and a continued ... fourth quarter 2015 is estimated to be higher than during ...
Breaking Biology News(10 mins):